Stephanie Salamanca
Family · Chicago, ILNPI 1083173066
Payments from drug & device makers
Across 349 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$2K
- AbbVie$681
- Novo Nordisk$534
- Merck$404
- Napo Pharmaceuticals Inc$354
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$7,833100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 99 | $2,156 |
| Gilead | 74 | $1,976 |
| AbbVie | 33 | $681 |
| Novo Nordisk | 22 | $534 |
| Merck | 15 | $404 |
| Napo Pharmaceuticals Inc | 26 | $354 |
| Lilly USA, LLC | 9 | $192 |
| Amgen | 9 | $183 |
| Axsome Therapeutics, Inc. | 7 | $151 |
| EMD Serono, Inc. | 7 | $150 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Novartis | 6 | $122 |
| Pfizer | 4 | $103 |
| Idorsia Pharmaceuticals US Inc | 1 | $99 |
| Theratechnologies Inc. | 4 | $94 |
| Corcept Therapeutics | 2 | $66 |
| GSK | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Johnson & Johnson(2 entities) | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Exact Sciences | 2 | $37 |
| Lundbeck LLC | 1 | $29 |
| Halozyme Inc | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| AstraZeneca | 1 | $22 |
| Exeltis, USA Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Organon | 1 | $15 |
How this compares
$7,848 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $51,551 |
| Lorazepam | 13 | $60 |
| Alprazolam | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $1,976 | $51,55111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in Chicago
- Ruth CarricoChicago$582K
- Jamie BroganChicago$282K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Brittony CroasdellChicago$192K
- Stephanie Bradley-MillerChicago$156K
- Elizabeth LegorretaChicago$150K
- Staci GorsonChicago$61K
- Allison MoserChicago$60K
- Darcie McDonaughChicago$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.